Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)

NASDAQ: NAMS · Pharmaceutical Preparations · Narrden, P7

Our rating: Cautious

Cautious reaffirmed at $27.83, moderate conviction, August 12, 2026.

Breaks if: The Cautious view would be wrong if the FDA approves obicetrapib with a label covering a broad LDL-lowering indication within 12 months of today, or if the company announces a new commercial or licensing partnership carrying at least $150M in upfront payments within the next two quarters — either event would demonstrate that the pipeline value embedded in the price is converting into clinical and commercial reality rather than remaining speculative, which would warrant a reassessment toward Positive.

Key figures

Market value$2.2B
Revenue, last 12 months$26M
Net income, last 12 months−$205M
Free cash flow, last 12 months−$151M
Price to earningsn/a
Free cash flow yield−6.8%
Dividend yield0.0%
Operating margin−900.1%
Return on equity−30.2%
Beta to the S&P 5001.08
Volatility, annualized61.2%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$19M5406.9%$-0.14−$40M
June 30, 2026$4M−80.7%$-0.52−$39M
March 31, 2026$3M2.1%$-0.40−$31M
December 31, 2025$32000.00−99.7%$-0.63−$41M
September 30, 2025$348000.00−98.8%$-0.61−$33M
June 30, 2025$19M740.1%$-0.15−$38M
March 31, 2025$3M112.6%$-0.34−$36M
December 31, 2024$13M1490.5%$-0.95−$37M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

12 ledger entries and 13 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.